Krystal Biotech's stock has surged by 7.03%, reaching a 52-week high amid a broader market decline, with the Nasdaq-100 down 0.40% and the S&P 500 down 0.42%.
The company reported anticipated Q4 2025 net revenue for VYJUVEK between $106 million and $107 million, with full-year revenue projected at $388 million to $389 million, showcasing its strong market potential in rare disease therapies. Additionally, Krystal plans to expand its clinical trial for KB801, increasing patient enrollment from 27 to 60, which reflects its commitment to addressing unmet medical needs in rare diseases.
This robust financial performance and strategic clinical development are likely to enhance investor confidence and position Krystal Biotech favorably in the competitive landscape of rare disease treatments.
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 229.25 USD with a low forecast of 198.00 USD and a high forecast of 278.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 229.25 USD with a low forecast of 198.00 USD and a high forecast of 278.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 272.910
Low
198.00
Averages
229.25
High
278.00
Current: 272.910
Low
198.00
Averages
229.25
High
278.00
Clear Street
Buy
maintain
$288 -> $338
2026-01-26
New
Reason
Clear Street
Price Target
$288 -> $338
AI Analysis
2026-01-26
New
maintain
Buy
Reason
Clear Street raised the firm's price target on Krystal Biotech to $338 from $288 and keeps a Buy rating on the shares. The shares have moved higher on Vyjuvek growth and building appreciation of its pipeline opportunities, the analyst tells investors in a research note. The firm says "most consistent excitement among investors" is being placed on Krystal's potential in the neurotrophic keratitis market with KB801. Clear cites increased estimates for KB801 for the target bump.
BofA
Buy
maintain
$288 -> $318
2026-01-22
Reason
BofA
Price Target
$288 -> $318
2026-01-22
maintain
Buy
Reason
BofA raised the firm's price target on Krystal Biotech to $318 from $288 and keeps a Buy rating on the shares. Beyond commentary on continued growth for Vyjuvek, the firm expects timelines for NK data will be tracked closely as it sees this as "the largest binary for shares this year," the analyst tells investors in an earnings preview for the group.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KRYS
Unlock Now
BofA
Buy
maintain
$272 -> $288
2026-01-09
Reason
BofA
Price Target
$272 -> $288
2026-01-09
maintain
Buy
Reason
BofA raised the firm's price target on Krystal Biotech to $288 from $272 and keeps a Buy rating on the shares. Following updates from the phase 1 CORAL-1 study, the firm continues to like Krystal as one of its top picks for the year as it thinks both Vyjuvek and the pipeline could unlock "significant value," the analyst tells investors.
TD Cowen
Buy
maintain
$202 -> $306
2026-01-09
Reason
TD Cowen
Price Target
$202 -> $306
2026-01-09
maintain
Buy
Reason
TD Cowen raised the firm's price target on Krystal Biotech to $306 from $202 and keeps a Buy rating on the shares. The firm updated its model following the release of robust Ph 1/2 407 data on in CF.
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
